Back to Results

Redhill Biopharma Ltd (RDHL)

Redhill Biopharma Ltd. is a biotechnology issuer whose ordinary shares are represented on NASDAQ through an American depositary receipt. The company concentrates on therapies in gastrointestinal and infectious disease areas. It markets Talicia for adults with H. pylori infection and Aemcolo for adults with travelers’ diarrhea. Redhill also reports a clinical-stage pipeline that includes five candidates spanning infectious disease, oncology, inflammatory conditions, and other indications. These include opaganib, RHB-107 (upamostat), RHB-104, RHB-102 (Bekinda), and RHB-204, with RHB-204 in Phase 3 development for pulmonary Mycobacterium avium complex disease in adults. The company was incorporated in 2009 and is based in Tel Aviv-Yafo, Israel.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-RDHL
$0.90
65.8% Upside
Bargain
Not available
Not available
Fair
0.0%
December 1, 2026
0.8x
11.5x
3.29 M
388.777 K
24.7%
82.5%
-70.6
89.1%
Valuation • Fair Value

Redhill Biopharma Ltd (NASDAQ-RDHL) Fair Value by Valuation Model

Review the available estimates for Redhill Biopharma Ltd (NASDAQ-RDHL), including Comps Fair Value.

Primary Valuation Read

Fair Value

$0.90

Estimated upside of 65.8% versus the current market price.

Fair Value Confidence

Very low

Confidence level for the primary fair value estimate.

Comps Fair Value

$0.90

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 3 available valuation references for Redhill Biopharma Ltd (NASDAQ-RDHL) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Redhill Biopharma Ltd (NASDAQ-RDHL)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

286 K

Current operating scale indicator.

Revenue Forecast

50.6 M

Forward revenue estimate.

EBITDA

-7.793 M

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Redhill Biopharma Ltd (NASDAQ-RDHL) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Redhill Biopharma Ltd (NASDAQ-RDHL)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

4

Mid-range quality score.

Altman Z-Score

-70.6

Lower score that deserves closer risk review.

FCF / Net Income

89.1%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Redhill Biopharma Ltd (NASDAQ-RDHL). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Redhill Biopharma Ltd (NASDAQ-RDHL)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

December 1, 2026

Days to Earnings

70

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Redhill Biopharma Ltd (NASDAQ-RDHL), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Redhill Biopharma Ltd (NASDAQ-RDHL) Stock Forecast & Technical Outlook

Review Redhill Biopharma Ltd (NASDAQ-RDHL) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Redhill Biopharma Ltd (NASDAQ-RDHL) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Redhill Biopharma Ltd (NASDAQ-RDHL) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Redhill Biopharma Ltd (NASDAQ-RDHL) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Redhill Biopharma Ltd (NASDAQ-RDHL) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Redhill Biopharma Ltd (NASDAQ-RDHL) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Redhill Biopharma Ltd (NASDAQ-RDHL)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Redhill Biopharma Ltd (NASDAQ-RDHL) has a Strong Buy consensus, with 1 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 0
Sell 0
FAQ • Fast Investor Answers

Redhill Biopharma Ltd (NASDAQ-RDHL) Stock FAQ

Data-supported answers about Redhill Biopharma Ltd (NASDAQ-RDHL), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$0.90
Estimated upside 65.8%
Valuation Rating
Undervalued
Estimated upside of 65.8%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Redhill Biopharma Ltd (NASDAQ-RDHL) is $0.90. This implies an estimated upside of 65.8% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 65.8% versus the current market price.

The current financial health read for Redhill Biopharma Ltd (NASDAQ-RDHL) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Redhill Biopharma Ltd (NASDAQ-RDHL) is December 1, 2026.

The latest available data indicates no current dividend yield for Redhill Biopharma Ltd (NASDAQ-RDHL).

The current market capitalization listed for Redhill Biopharma Ltd is 3.29 M.

The current enterprise value listed for Redhill Biopharma Ltd is 388.777 K. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Redhill Biopharma Ltd is NASDAQ-RDHL, and the stock is listed on NASDAQ.

Redhill Biopharma Ltd (NASDAQ-RDHL) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Redhill Biopharma Ltd is 24.7%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Redhill Biopharma Ltd is 82.5%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,043 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 648.7 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 372.3 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 269.8 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 175.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 159.2 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 127.2 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 102 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 101.9 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.536 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 46.053 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.268 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.639 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 30.107 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.733 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 15.616 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Overvalued Market Cap 12.702 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.456 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.639 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.564 B